^
Association details:
| Biomarker: | EGFR wild-type |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug: | Imfinzi (durvalumab) (PD-L1 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Patient reported outcomes (PROs) with 1L durvalumab (D), with or without tremelimumab (T), plus chemotherapy (CT) in metastatic (m) NSCLC: Results from POSEIDON
Published date:
03/23/2022
Excerpt:
Pts (n=1013) with EGFR/ALK wild-type mNSCLC were randomised (1:1:1)….Improvement rates in PROs, including prespecified symptoms/domains of interest, were greater for T + D + CT and D + CT vs CT alone....The addition of D (+/- T) to CT improved efficacy while delaying deterioration in health-related QoL in pts with mNSCLC. Pts in the T + D + CT and D + CT arms tended to have longer TTD and greater rates of improvement in global health status/QoL, functioning and symptoms vs pts in the CT arm.
Secondary therapy:
Chemotherapy
Trial ID:
Source:
Title:
A Global Study to Assess the Effects of Durvalumab + Domvanalimab Following Concurrent Chemoradiation in Participants With Stage III Unresectable NSCLC
Excerpt:
...Documented EGFR and ALK wild-type status (local or central)....
Trial ID:
Source:
Title:
Study to Assess Neoadjuvant Durvalumab (D) and Platinum-Based Chemotherapy (CT), Followed by Either Surgery and Adjuvant D or CRT and Consolidation D, in Resectable or Borderline Resectable Stage IIB-IIIB NSCLC (MDT-BRIDGE)
Excerpt:
...- EGFR and ALK wild-type....
Trial ID:
More C2 evidence
Source:
Title:
A Trial Evaluating Stereotactic Radiotherapy Plus Durvalumab Continuation for Patients With NSCLC Metachronous Oligometastatic Disease Under Durvalumab Consolidation Following Chemoradiation
Excerpt:
...Patient with wild type EGFR and ALK 12....
Trial ID:
Source:
Title:
A Global Study to Assess the Effects of Durvalumab + Domvanalimab Following Concurrent Chemoradiation in Patients With Stage III Unresectable Non-Small Cell Lung Cancer (PACIFIC 8)
Excerpt:
...Documented EGFR and ALK wild-type status (local or central). ...
Trial ID:
Source:
Title:
A multicentric Phase II, open-label study evaluating the efficacy of the combination of hypofractionated stereotactic radiation therapy with the anti-PDL1 immune checkpoint inhibitor Durvalumab in NSCLC patients with 1 to 4 Brain Metastases. Etude de phase II multicentrique en ouvert évaluant l’efficacité de l’association d’une radiothérapie hypofractionnée en conditions stéréotaxiques et de l’inhibiteur de checkpoint immunitaire anti-PDL1 durvalumab chez des patients porteurs de 1 à 4 métastases cérébrales de CBNPC.
Excerpt:
......
Trial ID:
Source:
Title:
89-Zirconium labeled MEDI4736 in MEDI4736 patients with non-small-cell lung cancer 89Zirconium gelabeled MEDI 4736 bij patiënten die worden behandeld met MEDI4736 voor niet-kleincellig longkanker
Excerpt:
...For inclusion in the study subjects must fulfill all of the following criteria:• Have a histologically or cytologically confirmed diagnosis of stage IV, EGFR wt and EML4-ALK fusion negative NSCLC and have received at least one line of platinum based doublet chemotherapy.• Written informed consent obtained from the subject prior to performing any protocol-related procedures, including screening evaluations • Age > 18 years at time of study entry• Have a World Health Organisation (WHO) performance status of 0 or 1 • Life expectancy of > 3 months. ...
Trial ID:
Less C2 evidence
Source:
Title:
Association of the Benefit of Durvalumab Consolidation Therapy and Driver Mutation Status for Locally Advanced Non-small Lung Cancer
Published date:
08/08/2023
Excerpt:
In this report, we examined the efficacy of durvalumab for patients with locally advanced, unresectable NSCLC at our institution. In addition, we focused on its efficacy in patients with driver mutations....In this retrospective analysis, durvalumab consolidation therapy following definitive chemoradiotherapy had a tendency to improve median PFS(group A 664 days [436-1069, 95%CI] vs group B 377days [282-451, 95%CI] p=0.053). The subgroup analysis of patients without driver mutations of EGFR, ALK or ROS-1 showed statistically longer median PFS by durvalumab consolidation (695 days [575-NA, 95%CI] vs 382 days [282-488, 95%CI], p<0.05)....
